“…PIC with PS HUVEC and lung carcinoma, in vitro [46,47] poly(ethylene oxide)-block-poly(α,β-aspartic acid)/poly([5-aminopentyl]-α,β-aspartamide) -lung carcinoma, in vitro [48] poly(ethylene oxide)-block-poly(α,β-aspartic acid) PIC with PS lung carcinoma, in vitro [49] poly(N-methyl-2-vinylpyridinium iodide)-block-poly(ethylene oxide) PIC with PS - [50,51] [64] poly(oligo(ethylene oxide)methyl ether methacrylate)-block-poly(ʟ-lysine) O 2 production image-guided (FI), liver and breast cancer, in vitro [65] methoxy-poly(ethylene oxide)-block-poly(ε-caprolactone)-benzyl degradation macrophages and endothelial cells, in vitro [40] poly(ethylene oxide)-block-poly(ε-caprolactone) degradation colon cancer and carcinoma, in vitro [37,66,67] poly(ethylene glycol)-block-poly(lactic acid) degradation [38] poly(ethylene glycol)-block-poly(ᴅ,ʟ-lactide-co-benzyl glycidyl ether) degradation macrophage and kidney cells, in vitro [45] poly(ethylene glycol)-block-poly(ε-caprolactone)-block- aliphatic polyesters, based for instance on ε-caprolactone or lactic acid [36][37][38][39][40][41]. In particular, the degradation of polyesters in vivo, a combination of both hydrolytic and enzymatic processes, makes them a first choice for the controlled delivery of drugs [42].…”